search
Back to results

CAR T Cells in Mesothelin Expressing Cancers

Primary Purpose

Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
huCART-meso cells
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Adenocarcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Histologically confirmed cancer (one of the following):

    1. Cohorts 1-4 and Cohort 6 participants:

      **Note: Cohorts 3 and 4 permanently closed**

      **Note: As of 1-Feb-2021 lung adenocarcinoma patients are no longer being enrolled in this trial**

      • Metastatic or recurrent lung adenocarcinoma.
      • Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma
      • Malignant pleural and peritoneal mesothelioma (histologically confirmed epithelial)
    2. Cohort 5 participants: **Note: As of 1-Feb-2021 lung adenocarcinoma patients are no longer being enrolled in this trial**

      • Metastatic or recurrent lung adenocarcinoma with documented pleural effusion
      • Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma with documented pleural effusion
      • Malignant pleural and peritoneal mesothelioma (histologically confirmed epithelial) with documented pleural effusion
    3. Cohort 7 patients:

      • Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma with evidence of ascites
      • Malignant peritoneal mesothelioma (histologically confirmed epithelial) with evidence of ascites **Note: Ascites does not need to be confirmed malignant by cytology.
  2. CRITERIA HAS BEEN RETIRED
  3. Failure of at least one prior standard of care chemotherapy for advanced stage disease. ALLOWANCE FOR PRIOR PD-1 or PDL-1 THERAPIES REMOVED.
  4. Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria (mesothelioma only).
  5. Subjects with asymptomatic CNS metastases that have been treated (and are off steroids for the treatment of CNS disease) are allowed. They must meet the following at the time of enrollment:

    1. No concurrent treatment for the CNS disease
    2. No progression of CNS metastasis on MRI at screening scans
    3. No evidence of leptomeningeal disease or cord compression
  6. Subjects ≥ 18 years of age.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. Satisfactory organ and bone marrow function as defined by the following:

    • Absolute neutrophil count ≥ 1,000/μl
    • Platelets ≥75,000/μl
    • Hemoglobin ≥ 8 g/dL
    • Bilirubin ≤ 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor
    • Creatinine ≤ 1.5x the institutional normal upper limit
    • Albumin ≥ 2
    • Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit viii.
    • Cardiac ejection fraction of ≥40% as measured by resting echocardiogram, with no clinically significant pericardial effusion.
  9. Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT ≤ 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters.
  10. Provide written informed consent.
  11. Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion Criteria

  1. Sarcomatoid mesothelioma histology which is known in the literature to not express mesothelin; biphasic mesothelioma is also excluded.
  2. Known leptomeningeal carcinomatosis or spinal cord compression. Screening for this is not required unless suspicious symptoms.
  3. Subjects with symptomatic CNS metastases are excluded.
  4. EXCLUSION CRITERIA HAS BEEN RETIRED
  5. Active invasive cancer other than the one of the three cancers in this study. Subjects with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded.
  6. HIV infection
  7. Active hepatitis B or hepatitis C infection
  8. Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within four (4) weeks prior to eligibility confirmation by physician-investigator, with the exception of thyroid replacement.
  9. Patients with ongoing or active infection.
  10. Planned concurrent treatment with systemic high dose corticosteroids. Subjects may be on a stable low dose of steroids (≤10mg equivalent of prednisone) for chronic respiratory conditions or adrenal insufficiency. Corticosteroids treatment as anti-emetic prophylaxis on the day of cyclophosphamide administration is allowed per institutional guidance.
  11. Patients requiring supplemental oxygen therapy.
  12. Prior therapy with lentiviral gene modified cells.
  13. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)
  14. Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heard Association Classification or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis, or which may worsen as a result of expected toxicities in this study. This determination will be made by a cardiologist if cardiac issues are suspected.
  15. Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches. An indwelling drainage device placed prior to eligibility confirmation by physician / investigator is acceptable.
  16. Pregnant or breastfeeding women.
  17. EXCLUSION HAS BEEN RETIRED
  18. Treatment with a PD-1 or PD-L1 inhibitor, including but not limited to nivolumab, pembrolizumab, atezolizumab, and/or durvalumab, within two (2) months prior to eligibility confirmation by investigator.
  19. Subjects with significant lung disease as follows:

    • Subjects with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden.
    • Subjects with radiographic and/or clinical evidence of active radiation pneumonitis.
    • Subjects with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.)

**No exceptions to eligibility will be granted.**

Sites / Locations

  • University of PennsylvaniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Cohort 5

Cohort 6

Cohort 7

Arm Description

Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells

Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells

PERMANENTLY CLOSED

PERMANENTLY CLOSED

Single dose of 1-3x107 huCART-meso cells/m2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.

Dose of 1-3x107 huCART-meso cells/m2 via IV infusion on Day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Cohort 6 was activated with Protocol V6. Enrollment into Cohort 6 will occur in parallel with Cohort 5.

a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. Infusion #1 for the first three subjects in Cohort 7 will be staggered by at least 21 days to allow for the assessment of DLTs. Enrollment into Cohort 7 will occur in parallel with Cohort 5 and Cohort 6.

Outcomes

Primary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

Secondary Outcome Measures

Clinical anti-tumor effect by standard criteria (RECIST)
Clinical anti-tumor effect by standard criteria [modified RECIST for mesothelioma]
Progression-free survival
Overall survival

Full Information

First Posted
February 9, 2017
Last Updated
September 18, 2023
Sponsor
University of Pennsylvania
Collaborators
National Institutes of Health (NIH), Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)
search

1. Study Identification

Unique Protocol Identification Number
NCT03054298
Brief Title
CAR T Cells in Mesothelin Expressing Cancers
Official Title
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 6, 2017 (Actual)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
National Institutes of Health (NIH), Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
Detailed Description
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells with and without cyclophosphamide and via different routes of administration. Cohort 1 (N=3-6): will receive a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells on day 0 without any conditioning chemotherapeutic regimen. Cohort 2 (N=3-6): will receive a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells on day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCARTmeso cells (day -4 to day -2). Cohort 3 (N=3-6): will receive a single dose of 1-3x10^8 /m^2 lentiviral transduced huCART-meso cells on day 0 without any conditioning chemotherapeutic regimen. **Cohort 3 permanently closed** Cohort 4 subjects (N=3-6) will receive a single dose of 1-3x10^8 /m^2 lentiviral transduced huCART-meso cells on day 0, following a flat dose of 1 gram/m^2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (day -4 to day -2). **Cohort 4 permanently closed** Cohort 5 (N=up to 6): will receive a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells on day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. The safety of this dose level has been established by Cohorts 1 and 2. Cohort 6 (N=up to 6): will receive lentiviral transduced huCART-meso cells at a dose of 1-3x10^7 via IV infusion on Day 0, following a flat dose of 1 gram/m^2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given between 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Enrollment into Cohort 6 will occur in parallel with Cohort 5. Cohort 7 (N = up to 6): will receive a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the 1st infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions . Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. The Maximum Tolerated Dose (MTD) is defined as the dose at which 0-1 DLT occurs in 6 evaluable subjects tested within the dose range of this study. The maximum tolerated dose has been established as 1-3x10^7/m^2 lentiviral transduced huCART-meso cells. Adverse events will be collected and evaluated during the protocol specified adverse event reporting period

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Mesotheliomas Pleural, Mesothelioma Peritoneum

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
27 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Active Comparator
Arm Description
Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
Arm Title
Cohort 2
Arm Type
Active Comparator
Arm Description
Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
Arm Title
Cohort 3
Arm Type
Active Comparator
Arm Description
PERMANENTLY CLOSED
Arm Title
Cohort 4
Arm Type
Active Comparator
Arm Description
PERMANENTLY CLOSED
Arm Title
Cohort 5
Arm Type
Active Comparator
Arm Description
Single dose of 1-3x107 huCART-meso cells/m2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.
Arm Title
Cohort 6
Arm Type
Active Comparator
Arm Description
Dose of 1-3x107 huCART-meso cells/m2 via IV infusion on Day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Cohort 6 was activated with Protocol V6. Enrollment into Cohort 6 will occur in parallel with Cohort 5.
Arm Title
Cohort 7
Arm Type
Active Comparator
Arm Description
a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. Infusion #1 for the first three subjects in Cohort 7 will be staggered by at least 21 days to allow for the assessment of DLTs. Enrollment into Cohort 7 will occur in parallel with Cohort 5 and Cohort 6.
Intervention Type
Biological
Intervention Name(s)
huCART-meso cells
Intervention Description
Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
Primary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Clinical anti-tumor effect by standard criteria (RECIST)
Time Frame
Day 28, Month 3 and 6
Title
Clinical anti-tumor effect by standard criteria [modified RECIST for mesothelioma]
Time Frame
Day 28, Month 3 and 6
Title
Progression-free survival
Time Frame
Year 2
Title
Overall survival
Time Frame
15 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Histologically confirmed cancer (one of the following): Cohorts 1-4 and Cohort 6 participants: **Note: Cohorts 3 and 4 permanently closed** **Note: As of 1-Feb-2021 lung adenocarcinoma patients are no longer being enrolled in this trial** Metastatic or recurrent lung adenocarcinoma. Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma Malignant pleural and peritoneal mesothelioma (histologically confirmed epithelial) Cohort 5 participants: **Note: As of 1-Feb-2021 lung adenocarcinoma patients are no longer being enrolled in this trial** Metastatic or recurrent lung adenocarcinoma with documented pleural effusion Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma with documented pleural effusion Malignant pleural and peritoneal mesothelioma (histologically confirmed epithelial) with documented pleural effusion Cohort 7 patients: Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma with evidence of ascites Malignant peritoneal mesothelioma (histologically confirmed epithelial) with evidence of ascites **Note: Ascites does not need to be confirmed malignant by cytology. CRITERIA HAS BEEN RETIRED Failure of at least one prior standard of care chemotherapy for advanced stage disease. ALLOWANCE FOR PRIOR PD-1 or PDL-1 THERAPIES REMOVED. Patients must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria (mesothelioma only). Subjects with asymptomatic CNS metastases that have been treated (and are off steroids for the treatment of CNS disease) are allowed. They must meet the following at the time of enrollment: No concurrent treatment for the CNS disease No progression of CNS metastasis on MRI at screening scans No evidence of leptomeningeal disease or cord compression Subjects ≥ 18 years of age. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Satisfactory organ and bone marrow function as defined by the following: Absolute neutrophil count ≥ 1,000/μl Platelets ≥75,000/μl Hemoglobin ≥ 8 g/dL Direct bilirubin ≤ 2.0 mg/dl unless secondary to bile duct obstruction by tumor. As of 23 November 2022 - inclusion of subjects with Gilbert's syndrome with a direct bilirubin of less that 3.0 mg/dl is allowed. Creatinine ≤ 1.5x the institutional normal upper limit Albumin ≥ 2 Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit viii. Cardiac ejection fraction of ≥40% as measured by resting echocardiogram, with no clinically significant pericardial effusion. Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT ≤ 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters. Provide written informed consent. Subjects of reproductive potential must agree to use acceptable birth control methods. Exclusion Criteria Sarcomatoid and biphasic mesothelioma. Known leptomeningeal carcinomatosis or spinal cord compression. Screening for this is not required unless suspicious symptoms. Subjects with symptomatic CNS metastases are excluded. EXCLUSION CRITERIA HAS BEEN RETIRED Active invasive cancer other than the one of the three cancers in this study. Subjects with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded. HIV infection Active hepatitis B or hepatitis C infection Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within four (4) weeks prior to eligibility confirmation by physician-investigator, with the exception of thyroid replacement. Patients with ongoing or active infection. Dependence on systemic steroids or immunosupressant medications. Patients requiring supplemental oxygen therapy. Prior therapy with lentiviral gene modified cells. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heard Association Classification or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis, or which may worsen as a result of expected toxicities in this study. This determination will be made by a cardiologist if cardiac issues are suspected. Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches. An indwelling drainage device placed prior to eligibility confirmation by physician / investigator is acceptable. Pregnant or breastfeeding women. EXCLUSION HAS BEEN RETIRED EXCLUSION HAS BEEN RETIRED Subjects with significant lung disease as follows: Subjects with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden. Subjects with radiographic and/or clinical evidence of active radiation pneumonitis. Subjects with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.) **No exceptions to eligibility will be granted.**
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abramson Cancer Center Clinical Trials Service
Phone
855-216-0098
Email
PennCancerTrials@careboxhealth.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janos L Tanyi, MD, PhD
Organizational Affiliation
University of Pennaylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abramson Cancer Center Clinical Trials Service
Phone
855-216-0098
Email
PennCancerTrials@careboxhealth.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

CAR T Cells in Mesothelin Expressing Cancers

We'll reach out to this number within 24 hrs